Table 3.
Statistical Comparisons of Survival by Antitoxin in Prelicensure Studies
| Phase | Arm | No. | Nonsurvivors, Mean ± SD Time to Death, h (min–max) | Survivors, n (%) |
P Values for Survival Comparisons vs Placebo (P < .05) |
|---|---|---|---|---|---|
| 1 | Raxibacumab | 16 | 83 ± 23 (54–115) | 10 (63) | .00032a |
| 1 | Placebo | 16 | 80 ± 19 (56–121) | 0 (0) | |
| 2 | Obiltoxaximab | 10 | 42 ± 8 (36–48) | 8 (80) | .024b |
| 2 | Placebo | 6 | 70 ± 23 (36–96) | 0 (0) |
Abbreviation: SD, standard deviation.
a
Time-to-death pairwise log-rank test analysis with Bonferroni correction; without Bonferroni correction, P = .00008.
b
Time-to-death pairwise log-rank test with Bonferroni correction, P = .05 is statistically significant; without Bonferroni correction, P = .006.